Abstract: The present invention relates to a method of treating an inflammatory condition, and to compounds and composition suitable for use in such a method, which compounds have the Formula: ##STR1## wherein: X is methylene, ethylene, ethyleneoxy, or oxygen;Q is ##STR2## where C' is a residue of a lipophilic amino acid, and Y is --CO.sub.2 H, --CH.sub.2 OH, --CONR.sub.1 R.sub.2, or --CO.sub.2 R.sub.1 where R.sub.1 and R.sub.2 hydrogen, alkyl, or aryl;R.sub.3 and R.sub.4 are, independently, hydrogen, alkyl or aryl; andA and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro;or pharmaceutically acceptable salts thereof.

Abstract: Mixed opiate agonist/antagonists, particularly buprenorphine, is provided for the treatment of cocaine dependence and concurrent cocaine and opiate abuse and dependence.

Abstract: A method of treating a learning deficiency is disclosed wherein a patient in need of stimulating learning ability is treated with a therapeutically effective amount of a compound of the Formula (I) ##STR1## wherein R.sup.1 is C.sub.1 to C.sub.8 straight or branched chain alkyl, C.sub.7 to C.sub.10 phenylalkyl, phenyl, or C.sub.3 to C.sub.8 cycloalkyl; andR.sup.2 is C.sub.1 to C.sub.8 straight or branched chain alkyl, unsubstituted or substituted by halogen, hydroxy, C.sub.1 to C.sub.4 alkoxy or by 1 or 2 phenyl groups; or is C.sub.3 to C.sub.8 cycloalkyl;with the proviso that R.sup.1 and R.sup.2 together contain at least 3 carbon atoms; or a pharmaceutically acceptable salt thereof.

Abstract: Amethod for inducing decrease in potassium ion concentration in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in inducing decrease in potassium ion concentration in the blood wherein said concentration is increased or for improving extracorporeal excretion of potassium ion in the blood which comprises administering, to a subject having an increased potassium ion concentration in the blood, a prostanoic acid derivative in an amount effective in improving extracorporeal excretion of potassium ion concentration is increased.

Abstract: A new composition, useful as a medicament, contains ascorbate, preferably as metallic salt(s), in combination with a dopamine agonist such as bromocriptine, with the ratio by weight of ascorbate to bromocriptine being 400:1 or greater. This combination, believed to act through stimulation of pituitary production of somatotropin, has a significant ability to stimulate enhanced lymphocyte function to result in method to reduce cholesterol levels in humans.

Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrane introduction into humans and other animals is disclosed.

Abstract: A method of healing extracellular matrix degradation to reverse glomerular sclerosis includes the steps of administering on angiotension I converting enzyme inhibitor and suppressing extracellular matrix release independent of the blood pressure effects of the enzyme inhibitor.

Abstract: A method for treatment of shock which comprises administering, to a subject in need of such treatment, a cyclodextrin or a derivative thereof in an amount effective in such treatment.

Abstract: A new synthetic antioxidant comprising an organogermanium compound represented by the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are one of a hydrogen atom, a substituted or unsubstituted phenyl group or an alkyl group, Y is a hydroxyl or amino group and Z is an oxygen or sulfur atom, is particularly effective in inhibiting auto-oxidation in living organisms.

Abstract: Method of diagnosing and treatment of sympathetically maintained pain. Sympathetically maintained pain is diagnosed and treated using the method of injecting or transdermally applying an .alpha.-adrenergic blocking agent selected from the group consisting of .alpha.-adrenergic antagonist, .alpha.-1-adrenergic antagonist, .alpha.2 adrenergic agonist, or other drug that depletes sympathetic norepineprhine. Sympathetic efferent fibers release norepinephrine which in turn activates .alpha.-adrenergic receptors. Activation of these receptors, either directly or indirectly, excites nociceptors. Activity in the nociceptors then evokes pain, and causes further discharge of nociceptors. Intravenous administration of phentolamine blocks the activation of .alpha.-adrenergic receptors which causes the pain to be relieved. The use of a clonidine, another .alpha.-adrenergic blocking agent, in a patch similarly achieved substantive pain reduction.

Abstract: Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures are provided comprising administering to a mammal in need of such treatment a retinoid such as etretinate.

Abstract: Persons suffering from negative symptoms of schizophrenia can be successfy treated using a histamine H.sub.2 -antagonist which crosses the blood-brain barrier so as to interact with histamine-H.sub.2 receptors in the brain. A preferred H.sub.2 -antagonist is famotidine. The H.sub.2 -antagonist may be used alone in patients who are relatively free of positive symptoms or it may be used in combination with known neuroleptics. A pharmaceutical composition containing both an H.sub.2 -antagonist and a neuroleptic is part of the present invention.

Abstract: A method of treating cerebral apoplexy in a patient in need thereof which comprises administering to said patient a amount effective therefor of a serotonin agonist which has an binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors.

Abstract: A pharmaceutical composition and process for preparing the same is provided, wherein the active ingredient of the said composition is one or more compounds of the general formula /I/ ##STR1## In the formula R is longer aliphatic hydrocarbon radical which may contain one or more unsaturation,R.sub.1 is hydrogen or longer aliphatic acyl radical which may contain one or more unsaturation,X is oxygen and Y is hydrogen, orX and Y, when taken together, form a radical of the formula .dbd.N--CH.sub.2 --CH.sub.2 --,z is 1 to 5, andq is 1 to 4.The use of the above compounds in the therapy of tumorous diseases and for regenerating tumorous cells and tissues is also claimed.

Abstract: The present invention relates to a method of treating or preventing a microbial infection, such as Pneumocystis carinii or Toxoplasma gondii, in a patient comprising administering to the patient an antimicrobially effective amount of p-acetamidobenzoic acid or a pharmaceutically acceptable salt thereof so that the microbial infection is inhibited. P-acetamidobenzoic acid or an acceptable salt thereof can be used to treat infections caused by Pneumocystis carinii, Toxoplasma gondii, Plasmodium species and other microorganisms containing the enzyme dihydropteroate synthetase such as most bacteria and some yeasts. The method of the present invention is particularly applicable in situations where the patient is immunosuppressed.

Abstract: There are disclosed a method for the treatment or prevention of immunoinflammatory conditions by administering to a mammal an effective amount of a compound having the formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each, independently, hydrogen, alkyl, aralkyl, aryl, or ##STR2## X is alkyl, aryl, or -NR.sup.5 R.sup.6 ; R.sup.5 and R.sup.6 are each independently hydrogen, alkyl, or aryl; aryl is ##STR3## where the dotted line represents an optional double bond; R.sup.7, and R.sup.8 and R.sup.9 are each, independently, hydrogen, alkyl, hydroxy, alkoxy, carbalkoxy, halo, nitro, amino, cyano, trifluoromethyl, or a carboxylic acid;n=1-3;or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides trans-3,4 1-substituted-3-substituted-4-methyl-4-(3-substituted phenyl)piperidines as opioid antagonists capable of blocking the mu or kappa receptors in the brain.

Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs 13-(substituted mercapto) derivatives of tetracycline in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously or concurrently. The concomittantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state. The combination also effects a synergistic bacteriocidal activity against susceptible and resistant cells.

Abstract: The present invention relates to a method of inhibiting superoxide generation which comprises administering to a mammal in need of such treatment an amount of a compound of the Formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and independently represent tert-alkyl or phenyl; Alk.sup.1 represents straight or branched chain alkylene of 1 to 10 carbon atoms, X represents sulfur or oxygen, Alk.sup.2 represents straight or branched chain alkylene of 1 to 4 carbon atoms; and m is 0, 1 or 2; or a pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof, which is effective to inhibit superoxide generation.

Abstract: Certain derivatives of oxophthalazinyl acetic acids of the formula ##STR1## wherein R.sub.1 is hydroxy or a prodrug group, and R.sub.2 and R.sub.3 are independently hydrogen, fluoro, chloro or trifluoromethyl, except that R.sub.2 and R.sub.3 are not both hydrogen, or a pharmaceutically acceptable base addition salt of a compound of formula I wherein R.sub.1 is hydroxy, are capable of lowering blood uric acid levels in mammals. These oxophthalazinyl acetic acid derivatives are for instance useful for treating gout and gouty arthritis in a mammal .